Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

CMS Research Policy May Deny Coverage For Hundreds Of Device Trials

This article was originally published in The Gray Sheet

  • News

Executive Summary

CMS' proposed Clinical Research Policy has generated widespread concern within the device industry about its potential to restrict Medicare support for clinical trials

You may also be interested in...



Self-Certification For Trial Coverage Will Be Easy, Says CMS

CMS is trying to make it simple for clinical trial sponsors and investigators to get reimbursed by Medicare for routine costs

Self-Certification For Trial Coverage Will Be Easy, Says CMS

CMS is trying to make it simple for clinical trial sponsors and investigators to get reimbursed by Medicare for routine costs

CMS Sticks To Status Quo On Clinical Research Coverage, For Now

Major revisions to CMS' policy on covering clinical research costs were put on hold July 9 in response to stakeholder demands for more input

Table

View full table

Related Content

Medtech Insight
Medtech Insight
Tags:
Latest Headlines

It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight

Mini-Slings Are Comparable To Traditional Ones To Treat Incontinence, FDA Says

Ekso's Exoskeleton Receives Medicare Coverage, Paves Way To Faster Rehabilitation

EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency

See All
UsernamePublicRestriction

Register

MT024813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By